For immunochemical detection of LDLR
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

LDL Receptor Polyclonal Antibody - Biotinylated

Item No. 22727

Technical Information
Synonyms
  • LDLR
  • Low Density Lipoprotein Receptor
Immunogen
Synthetic peptide from the C-terminal region of mouse LDLR
MW
~100-160 kDa
50 μg of biotinylated IgG
Storage Buffer
PBS, pH 7.2, 50% glycerol, 0.1% BSA, and 0.02% sodium azide
Host
Rabbit
Applications
ICC, WB
Cross Reactivity
(+) LDLR
Species Reactivity
(+) Human(+) Mouse(+) Rat
UniProt Accession №
P35951 (murine)
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    LDL receptor (LDLR) is a cell surface glycoprotein that scavenges LDL from the blood and regulates plasma LDL levels.1 It is composed of an N-terminal signal sequence, a ligand-binding domain, an EGF precursor homology domain, an O-linked glycosylation domain, a transmembrane region, and a C-terminal cytoplasmic tail. LDLR is primarily expressed in the liver but is also found in the adrenal cortex.2 It mediates the endocytosis of LDL by binding to apolipoprotein E (ApoE) or ApoB on the LDL surface, thereby supplying cholesterol to cells.1 Protein levels of LDLR are decreased in HepG2 cells expressing proprotein convertase subtilisin kexin 9 (PCSK9).3 Knockout of Ldlr increases plasma levels of cholesterol and triglycerides and induces the formation of atherosclerotic lesions in mice.4 Mutations in LDLR are associated with familial hypercholesterolemia.5 Cayman's LDL Receptor Polyclonal Antibody - Biotinylated is composed of an LDLR polyclonal antibody conjugated to biotin and can be used for immunocytochemistry (ICC) and Western blot (WB) applications. This antibody recognizes LDLR at approximately 100 to 160 kDa from human, mouse, and rat samples.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Goldstein, J.L., Brown, M.S., Anderson, R.G.W., et alReceptor-mediated endocytosis: Concepts emerging from the LDL receptor system. Annu. Rev. Cell Biol. 1, 1-39 (1985).

    2. Rudling, M.J., Reihnér, E., Einarsson, K., et alLow density lipoprotein receptor-binding activity in human tissues: Quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo. Proc. Natl. Acad. Sci. USA 87(9), 3469-3473 (1990).

    3. Benjannet, S., Rhainds, D., Essalmani, R., et alNARC-1/PCSK9 and its natural mutants. Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. The Journal of Biological Chemisty 279(47), 48865-48875 (2004).

    4. Praticò, D., Tillmann, C., Zhang, Z.B., et alAcceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl. Acad. Sci. USA 98(6), 3358-3363 (2001).

    5. Austin, M.A., Hutter, C.M., Zimmern, R.L., et alGenetic causes of monogenic heterozgous familial hypercholesterolemia: A HuGE prevalence review. Am. J. Epidemiol. 160(5), 407-420 (2004).